YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
Activists also report to the SEC on Allot Communications, Genco Shipping & Trading, Aurinia Pharmaceuticals, and Turtle Beach. Continue Reading
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
Quick Read Moderna's 177% stock surge to a ~$70B market cap makes ABUS a prime target, as buying it eliminates $1.3B in LNP patent exposure. NTLA's Phase 3 lonvo-z showed 87% fewer hereditary angioedema attacks, while EDIT offers cardiomet…
* Immatics press release [https://seekingalpha.com/pr/20621874-immatics-announces-second-quarter-2026-financial-results-and-business-update] (IMTX [https://seekingalpha.com/symbol/IMTX]): Q2 GAAP EPS of -€0.46. * Revenue of €9.14M (+92.8%…
Moderna MRNA announced that it has dosed the first U.S. patient in a phase I study evaluating mRNA-4200, an investigational off-the-shelf, tumor-targeted cancer antigen therapy. The study will assess the safety and tolerability of the cand…
IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer In head and neck cancer, IMA401 treatment at recommended Phas…
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR),…
Acadia Pharmaceuticals ACAD reported first-quarter 2026 earnings per share (EPS) of 2 cents, which missed the Zacks Consensus Estimate of 4 cents. In the year-ago quarter, the company had reported EPS of 11 cents. In the first quarter, Aca…
Madrigal Pharmaceuticals MDGL reported first-quarter 2026 loss of $3.25 per share, narrower than the Zacks Consensus Estimate of a loss of $3.61. In the same quarter last year, the company had incurred a loss of $2.61 per share. In the fir…
Recursion Pharmaceuticals RXRX reported a loss of 22 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had incurred a loss of 50 cents per share in the year-ago quar…
Novo Nordisk A/S NVO reported adjusted first-quarter 2026 earnings of $1.04 per American Depositary Receipt (ADR), which beat the Zacks Consensus Estimate of 87 cents. The company had reported adjusted earnings of 96 cents per ADR in the y…
Twist Bioscience (TWST) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. Th…
Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR provided by Immatics 17-year-old adolesc…
Immatics N.V. (NASDAQ:IMTX) is among the best German stocks to buy according to analysts. On March 5, Immatics N.V. (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also provided updates on its business.Immat…
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items. T…
The US biotechnology sector is poised for growth in 2026, with several companies having near-term ca PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it…
Shares of Aramark (ARMK) tumbled 5.2% after the company reported fourth-quarter fiscal 2025 earnings of $0.64 per share, missing the Zacks Consensus Estimate of $0.65 per share. J&J Snack Foods Corp.’s (JJSF) shares gained 1.1% after the c…
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.57 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.3 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago,…
Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line pati…
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago. These figures are adjusted for non-recurring item…
* Immatics N.V. (NASDAQ:IMTX [https://seekingalpha.com/symbol/IMTX]) has appointed Venkat Ramanan as chief financial officer, effective immediately. * Ramanan brings 25+ years of biopharma finance experience, with leadership roles at Seage…
https://immatics.com/ Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, tod…
Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appoi…
Investing.com - Mizuho has reiterated an Outperform rating and $16.00 price target on Immatics (NASDAQ:IMTX) following the company’s second-quarter 2025 financial results reported last week. According to InvestingPro data, analyst targets…
Investing.com - Immatics NV (NASDAQ: IMTX) reported second quarter EPS of €-0.58, €0.28 worse than the analyst estimate of €-0.30. Revenue for the quarter came in at €5.5M versus the consensus estimate of €13.37M. Immatics NV’s stock price…
Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: One-time infusion continues to show favorable tolerability as well as strong anti-tumor activity and durability in 33 heavily pretreated patients with metastatic melanoma in da…
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring…
Immatics N.V. (NASDAQ:IMTX) is among the 13 Best German Stocks to Invest in Now. On May 31, the company shared results from the ongoing Phase 1b clinical trial evaluating the efficacy of IMA203 PRAME cell therapy in heavily pretreated pati…
[Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research. Working on Computers, Analyzing Samples] gorodenkoff/iStock via Getty Images Im…
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immatics (NASDAQ:IMTX) stands against other biotech penny stocks. Peter Marks’s departu…
We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immatics (NASDAQ:IMTX) stands against other best German stocks to buy according to hedge funds. Ge…
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stocks…
https://immatics.com/ Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immun…